Azithromycin to Reduce Mortality — An Adaptive Cluster-Randomized Trial

In this trial, rural communities in Niger were randomly assigned to distribute azithromycin or placebo to children (1 to 59 months of age) or infants (1 to 11 months). All-cause mortality was reduced in the child-treated group.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-08, Vol.391 (8), p.699-709
Hauptverfasser:	O’Brien, Kieran S., Arzika, Ahmed M., Amza, Abdou, Maliki, Ramatou, Aichatou, Bawa, Bello, Ismael Mamane, Beidi, Diallo, Galo, Nasser, Harouna, Naser, Karamba, Alio M., Mahamadou, Sani, Abarchi, Moustapha, Ibrahim, Almou, Lebas, Elodie, Peterson, Brittany, Liu, Zijun, Le, Victoria, Colby, Emily, Doan, Thuy, Keenan, Jeremy D., Oldenburg, Catherine E., Porco, Travis C., Arnold, Benjamin F., Lietman, Thomas M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptation Age composition Age groups Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Antibiotics Antimicrobial resistance Azithromycin Azithromycin - administration & dosage Azithromycin - adverse effects Babies Bacterial Infections Bacterial Infections - mortality Bacterial Infections - prevention & control Caregivers Censuses Chemoprevention - adverse effects Chemoprevention - statistics & numerical data Child Mortality Child, Preschool Childhood Diseases Children Children & youth Community Consent Drug Resistance, Bacterial Female Global Health Humans Infant Infant Mortality Infants Infectious Disease Infectious Disease General Malaria Male Mass Drug Administration - adverse effects Mass Drug Administration - statistics & numerical data Mortality Niger - epidemiology Pediatrics Pediatrics General Placebos Probability Rural Population - statistics & numerical data Standard deviation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this trial, rural communities in Niger were randomly assigned to distribute azithromycin or placebo to children (1 to 59 months of age) or infants (1 to 11 months). All-cause mortality was reduced in the child-treated group.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2312093